Subconjunctival corticosteroid injection for the treatment of non-necrotising anterior scleritis
نویسندگان
چکیده
منابع مشابه
Subconjunctival corticosteroid injection for the treatment of non-necrotising anterior scleritis.
Scleritis commonly is a recurrent disease that requires long term immunosuppressive treatment that can be associated with significant adverse effects. Although topical and periorbital steroids are accepted therapeutic options for treatment of scleritis, subconjunctival administration of depot corticosteroids has been considered unsafe owing to the risk of scleral thinning and perforation. Recen...
متن کاملSubconjunctival corticosteroid injection for the treatment of non- necrotising anterior scleritis
Scleritis commonly is a recurrent disease that requires long term immunosuppressive treatment that can be associated with significant adverse effects. Although topical and periorbital steroids are accepted therapeutic options for treatment of scleritis, subconjunctival administration of depot corticosteroids has been considered unsafe owing to the risk of scleral thinning and perforation. Recen...
متن کاملSubconjunctival dexamethasone implant for non-necrotizing scleritis
BACKGROUND The purpose of this study is to report the management of non-necrotizing anterior scleritis with a single-dose subconjunctival 0.7 mg dexamethasone implant (Ozurdex®, Allergan, Inc., CA, USA). Six patients with clinical diagnosis of non-necrotizing anterior scleritis (diffuse, sectorial, and nodular) were submitted to subconjunctival injection of dexamethasone implant. The injection ...
متن کاملImmunopathology of necrotising scleritis.
AIM To detect the immunohistopathology of necrotising scleritis. METHODS Immunohistochemical staining was performed on two groups of enucleated eyes with necrotising scleritis (systemic autoimmune disease and idiopathic scleritis). Deparaffinised sections were stained with CD3, CD20, CD68, CD8, CD4 and dendritic reticulum cells (DRC). RESULTS Within the autoimmune group, about 43% of inflam...
متن کاملSubconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial.
PURPOSE To investigate the safety, tolerability and efficacy of subconjunctival sirolimus injections as a treatment for active, autoimmune, non-necrotizing anterior scleritis. DESIGN Phase I/II, single-center, open-label, nonrandomized, prospective pilot study. METHODS Five participants with active, autoimmune, non-necrotizing anterior scleritis with scleral inflammatory grade of ≥1+ in at ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Ophthalmology
سال: 2005
ISSN: 0007-1161
DOI: 10.1136/bjo.2004.052738